Avalyn Pharma Inc. Common Stock
AVLN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$37.39
▲ +5.50%
P/E
-28.98
Mkt Cap
$1.7B
52-Wk Range
$24.15–$40.17
52-Week Range
$24.15 - $40.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 26.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on inhaled respiratory therapeutics
- Proprietary drug delivery technology for lung diseases
- Expert management team with deep biopharmaceutical experience
- First-mover advantage in targeted rare respiratory disease markets
Bear Case
1 risk
- Low volatility (beta -1.1).
Growth
Stable outlook
Progression of clinical-stage candidates through development pipeline
Value
Deep value opportunity - significant discount to Healthcare Distribution peers
Momentum
Hot
+33.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AVLN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 12, 2026
Reported EPS of -$0.98 vs -$0.78 consensus (-26.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-26.2%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 13, 2026
vs Industry
How AVLN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related